Oragenics (NYSEAMERICAN:OGEN) Stock Crosses Above Two Hundred Day Moving Average of $0.00
Oragenics (NYSEAMERICAN:OGEN) Stock Crosses Above Two Hundred Day Moving Average of $0.00
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.95. Oragenics shares last traded at $2.73, with a volume of 8,844 shares trading hands.
Oragenics 股份有限公司（紐約美洲：OGEN-獲取評級）在周五交易期間超過其 200 天移動平均線。該股票的 200 日移動平均線為 0.00 美元，交易高達 2.95 美元。Oragenics 股票最後交易價為 2.73 美元，交易量為 8,844 股。
Oragenics Stock Down 1.4 %
天然股票下降 1.4%
The company has a market cap of $5.35 million, a P/E ratio of -21.00 and a beta of 0.19.
該公司的市值為 535 萬美元，市盈率為 -21.00，測試版為 0.19。
Hedge Funds Weigh In On Oragenics
對沖基金權衡天然
Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp boosted its stake in Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock worth $171,000 after purchasing an additional 37,338 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Oragenics by 116.5% during the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 112,800 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 110,119 shares during the last quarter. Institutional investors and hedge funds own 9.31% of the company's stock.
機構投資者和對沖基金最近買賣了該業務的股票。州街公司在第一季度將其在 Oragenics 的股份提高了 8.1％。州街公司現在擁有該生物技術公司股票的 495,563 股價值 171,000 美元的股票，在上個季度額外購買 37,338 股。文藝復興科技有限責任公司在第二季度提高了其在 Oragenics 股份的地位 116.5％。文藝復興技術有限責任公司現在擁有 209,600 股生物技術公司的股票價值 $73,000 在最後一個季度獲得了額外的 112,800 股票後。最後，千禧管理有限責任公司在第二季度提高了 591.6％ 的 Oragenics 股份的地位。千年管理有限責任公司現在擁有 128,733 股生物技術公司的股票價值 45,000 美元後，在上個季度額外購買 110,119 股。機構投資者和對沖基金擁有公司股票的 9.31%。
Oragenics Company Profile
天然公司簡介
(Get Rating)
(取得評分)
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Oragenics 公司在美國開發用於傳染病的抗生素。該公司從事 NT-CoV2-1（一種提供新型嚴重急性呼吸系統綜合徵冠狀病毒免疫力的鼻內疫苗候選疫苗）的開發和商業化；以及 Terra CoV-2（一種提供新型嚴重急性呼吸系統綜合症冠狀病毒的免疫力）的肌內疫苗候選疫苗。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 10 Best Consumer Discretionary ETFs
- 5 Best Dividend Capture Stocks
- 獲取有關 Ogenics 的研究報告的免費副本
- 股息王原廠配件公司升級的利潤指導
- 底部是在埃森哲
- 11 股 2023 年最佳非必要消費品股票
- 10 大最佳自選消費型 ETF
- 5 個最佳股息捕捉股票
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics 日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Oragenics 和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。